“医二代”变多,日本网红眼药水被召回,默沙东K药单药疗法三期失败

2019-05-26 佚名 医师报

行业新闻 1、“医二代”不是少了,而是一年比一年多 5月19日,上海交通大学医学院举办“校园开放日”活动,数百名考生及家长前来参观。除外单位外,交大医学院自身附属的十多家医院中,医生子女选择本校考医的也不少


行业新闻

1、“医二代”不是少了,而是一年比一年多

5月19日,上海交通大学医学院举办“校园开放日”活动,数百名考生及家长前来参观。除外单位外,交大医学院自身附属的十多家医院中,医生子女选择本校考医的也不少。

分管教学的学院副院长胡翊群告诉记者:“我很难理解为什么社会上有一种说法:医生不愿意让自己孩子做医生——在我看来,这种现象并不存在。至少我们这样的学校,近年来‘医二代’甚至‘医三代’,不是更少,而是更多,而且一年比一年多。”

(来源:上观新闻)

2、第72届世界卫生大会开幕,中国医改经验引世界瞩目

日内瓦当地时间5月18日,在第72届世界卫生大会上,中国代表团在日内瓦召开记者会。会议介绍了中华人民共和国成立70周年来卫生健康领域的进展与变化。国家卫生健康委新闻发言人、宣传司司长宋树立表示,70年来,中国人均预期寿命从35岁增长到77岁,主要健康指标优于中高收入国家平均水平。中国始终把实现全民健康覆盖,人人享有基本医疗卫生服务作为重要奋斗目标,积极探索适合国情的发展道路,取得了重大阶段性成效,为全球卫生治理贡献了中国经验和中国力量。

(来源:健康中国)

3、国务院,对美国重组胰岛素等50种药物及医疗用品加征25%关税

日前,国务院关税税则委员会发布《关于对原产于美国的部分进口商品提高加征关税税率的公告》。公告指出,自2019年6月1日起,对原产于美国约600亿美元的进口商品实施加征关税税率。其中,重组胰岛素等50种进口美国药物及医疗用品加征25%的关税,具体加征药品名单详见下文。

(来源:丁香园)

学术新闻

4、美国80%的维生素软糖不符合膳食补剂标准

近日,美国“消费实验室网站”对美国和加拿大销售的50种流行复合维生素产品(包括5种品牌维生素软糖)进行调查发现,尽管维生素软糖味甜可口,但却无法提供适当营养,反而可能会伤害身体。

研究结果显示,80%的维生素软糖(胶状维生素)不符合膳食补剂相关标准,一些维生素产品所含营养素与标签上注明的情况相差甚远。其中,12种复合维生素所含营养素比标签上所列营养素少24%,有4种产品的维生素A严重超标。(来源:健康时报)

5、因含处方成分4款日本网红眼药水被加拿大下架召回

近日,加拿大卫生部官网召回6款在售的日本产品,其中4款眼药水因含有处方药成分氨基己酸和新斯的明甲基硫酸盐成分,这些眼药水有较多副作用,包括红眼、白内障、过敏反应、虹膜囊肿、视网膜脱离等,目前这些药物已经不再被广泛使用。

记者经查阅国内电商平台发现,同款眼药水在国内销售势头很旺,其中最高月售将近4万瓶。

(来源:健康时报)

6、默沙东Keytruda单药治疗三阴性乳腺癌三期试验宣告失败

5月20日,默沙东公布了K药(可瑞达,pembrolizumab)作为单药疗法的三期KEYNOTE-119试验数据,此次试验的对象是先前接受过治疗的转移性三阴性乳腺癌(TNBC)患者。试验结果显示,与化疗(包括卡培他滨、艾日布林、吉西他滨或长春瑞滨)相比,试验中的TNBC患者的总生存期的改善未达到预定的主要终点。

(来源:新浪医药新闻)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-10-05 siiner
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-05-28 yese
  6. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-05-28 caoliehu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1932275, encodeId=36a819322e5f4, content=<a href='/topic/show?id=903b33802cb' target=_blank style='color:#2F92EE;'>#医二代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33802, encryptionId=903b33802cb, topicName=医二代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Tue Feb 25 21:42:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717487, encodeId=c3d91e17487ef, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Mon Aug 05 15:42:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811395, encodeId=8a2f181139556, content=<a href='/topic/show?id=1cd88e9322a' target=_blank style='color:#2F92EE;'>#药疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87932, encryptionId=1cd88e9322a, topicName=药疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Oct 05 06:42:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990497, encodeId=476f199049ed8, content=<a href='/topic/show?id=ccd7e94800a' target=_blank style='color:#2F92EE;'>#网红眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79480, encryptionId=ccd7e94800a, topicName=网红眼药水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Oct 02 13:42:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294469, encodeId=f5ed129446971, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404235, encodeId=b7841404235a6, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489269, encodeId=ff471489269f9, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Tue May 28 14:42:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]